Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder
Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 PlannedCHENGDU, China and ROCKAWAY, N.J., M
